PVR and neoplasm: Our observations reported in this work demonstrate that Fc engagement is necessary and required for anti-tumor efficacy of antagonist anti-TIGIT antibodies, and that blocking the TIGIT:CD155 interaction alone is not sufficient to confer anti-tumor efficacy of antagonist anti-TIGIT antibodies.